Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies

被引：44
|
作者：
Schoenfeld, Kurt [1 ]
Zuber, Chantal [1 ]
Pinkas, Jan [2 ]
Haeder, Thomas [1 ]
Bernoester, Katrin [1 ]
Uherek, Christoph [1 ]
机构：
[1] Biotest AG, Landsteinerstr 5, D-63303 Dreieich, Germany
[2] ImmunoGen Inc, 830 Winter St, Waltham, MA 02451 USA
来源：
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2017年 / 10卷
关键词：
Multiple myeloma; Pre-clinical; Indatuximab ravtansine; Drug combination; Tumour regression; AGENTS;
D O I：
10.1186/s13045-016-0380-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Indatuximab ravtansine is a monoclonal antibody-linked cytotoxic agent that specifically targets CD138-expressing cells. Monotherapy has been shown to significantly inhibit multiple myeloma tumour growth in vivo and improve host survival. Here, we show that in most cell lines tested, indatuximab ravtansine acts additively or even synergistically with clinically approved therapies for treatment of multiple myeloma. In addition, in vivo mouse xenograft models confirmed the activity of indatuximab ravtansine in combination with lenalidamide and lenalidomide/ dexamethasone. Indatuximab ravtansine may therefore be a suitable combination partner for multiple myeloma, and a clinical study is ongoing.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
    Kurt Schönfeld
    Chantal Zuber
    Jan Pinkas
    Thomas Häder
    Katrin Bernöster
    Christoph Uherek
    Journal of Hematology & Oncology, 10
  • [2] Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma
    Jagannath, Sundar
    Heffner, Leonard T., Jr.
    Ailawadhi, Sikander
    Munshi, Nikhil C.
    Zimmerman, Todd M.
    Rosenblatt, Jacalyn
    Lonial, Sagar
    Chanan-Khan, Asher
    Ruehle, Markus
    Rharbaoui, Faiza
    Haeder, Thomas
    Wartenberg-Demand, Andrea
    Anderson, Kenneth C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (06): : 372 - 380
  • [3] Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma
    Kelly, Kevin R.
    Siegel, David S.
    Chanan-Khan, Asher A.
    Somlo, George
    Heffner, Leonard T.
    Jagannath, Sundar
    Zimmerman, Todd
    Munshi, Nikhil C.
    Madan, Sumit
    Mohrbacher, Ann
    Lonial, Sagar
    Barmaki-Rad, Farima
    Ruhle, Markus
    Herrmann, Eva
    Wartenberg-Demand, Andrea
    Haeder, Thomas
    Anderson, Kenneth C.
    BLOOD, 2016, 128 (22)
  • [4] Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib
    Kelly, Kevin R.
    Chanan-Khan, Asher
    Heffner, Leonard T.
    Somlo, George
    Siegel, David S.
    Zimmerman, Todd
    Karnad, Anand
    Munshi, Nikhil C.
    Jagannath, Sundar
    Greenberg, Allen L.
    Lonial, Sagar
    Roy, Vivek
    Ailawadhi, Sikander
    Barmaki-Rad, Farima
    Chavan, Shailesh
    Patel, Pankaj
    Wartenberg-Demand, Andrea
    Haeder, Thomas
    Anderson, Kenneth C.
    BLOOD, 2014, 124 (21)
  • [5] Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients
    Kelly, Kevin R.
    Chanan-Khan, Asher
    Somlo, George
    Heffner, Leonard T.
    Siegel, David S.
    Zimmerman, Todd M.
    Jagannath, Sundar
    Munshi, Nikhil C.
    Lonial, Sagar
    Roy, Vivek
    Ruehle, Markus
    Chavan, Shailesh
    Patel, Pankaj
    Rothenburger, Markus
    Wartenberg-Demand, Andrea
    Haeder, Thomas
    Anderson, Kenneth C.
    BLOOD, 2013, 122 (21)
  • [6] Pre-clinical studies in support of the clinical development of Aplidin® (APL) for the treatment of Multiple Myeloma (MM).
    Mitsiades, CS
    Mitsiades, N
    McMullan, CJ
    Faircloth, G
    Martin, JAL
    Otero-Serrano, G
    Anderson, KC
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6204S - 6204S
  • [7] Pre-clinical studies in support of the clinical development of aplidin® (APL) for the treatment of multiple myeloma (MM).
    Mitsiades, CS
    McMullan, CJ
    Mitsiades, N
    Faircloth, G
    Lopez-Martin, JA
    Otero-Serano, G
    Anderson, KC
    BLOOD, 2003, 102 (11) : 74A - 74A
  • [8] BT062, a CD138-Specific Immunoconjugate, Demonstrates Superior In Vivo Anti-Myeloma Efficacy In Combination with Lenalidomide or Bortezomib
    Zuber, Chantal
    Daelken, Benjamin
    Aigner, Silke
    Haeder, Thomas
    Ab, Olga
    Whiteman, Kathleen
    Hideshima, Teru
    Lutz, Robert J.
    Osterroth, Frank
    Uherek, Christoph
    BLOOD, 2010, 116 (21) : 1239 - 1240
  • [9] BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
    Jagannath, Sundar
    Chanan-Khan, Asher
    Heffner, Leonard T.
    Avigan, David
    Zimmerman, Todd M.
    Lonial, Sagar
    Lutz, Robert J.
    Engling, Andre
    Uherek, Christoph
    Osterroth, Frank
    Ruehle, Markus
    Beelitz, Michelle A.
    Niemann, Gabriele
    Wartenberg-Demand, Andrea
    Haeder, Thomas
    Anderson, Kenneth C.
    Munshi, Nikhil C.
    BLOOD, 2011, 118 (21) : 142 - 143
  • [10] Adenovirus mediated immunogene therapy for the treatment of myeloma: Pre-clinical and clinical studies
    Stewart, AK
    LEUKEMIA & LYMPHOMA, 1998, 30 : 13 - 14
12345